Agomab Therapeutics NV（AGMB）價格預測

$13.540

+0.380 (+2.81%)收盤時

價格預測

1-Day Price Prediction

-1.41%

1-Week Prediction

-1.70%

1-Month Prediction

—

2026 Prediction

—

2030 Prediction

—

在 App 中開啟以解鎖更長週期的預測。

Loading chart…

AGMB 相似圖表分析預測

Alphio's AGMB stock price prediction model matches the current Agomab Therapeutics NV tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $13.35 (-1.41%). The 1-week path is $13.31 (-1.70%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

該買進 Agomab Therapeutics NV 股票嗎？

Agomab Therapeutics appears to be a good buy right now due to its promising clinical developments and strong analyst support. The stock is currently priced at $13.17, significantly below the average analyst price target of $43.33, indicating substantial upside potential. Additionally, the recent initiation of a Phase 2b trial for its drug Ontunisertib in Crohn's disease aligns with a growing market projected to reach $13.20 billion by 2023, further enhancing its growth prospects. However, the company reported a negative EPS of -0.71 for Q3 2024, which is a risk to consider.